U.S. General Merchandise and Department Stores Stock News

NasdaqGM:WINA
NasdaqGM:WINASpecialty Retail

Winmark (WINA) Stock Faces High P/E As 47% Net Margin Softens Bullish Narratives

Winmark (WINA) has put fresh numbers on the table for Q2 2026, with total revenue of US$22.0 million and basic EPS of US$2.90, supported by trailing twelve month revenue of US$86.5 million and EPS of US$11.42 that sit alongside a 47.1% net margin, slightly below 49.5% a year earlier. Over recent quarters the company has seen revenue move within a tight band between US$20.4 million and US$22.6 million per quarter, while quarterly EPS has ranged from about US$2.59 to US$3.13. This backdrop...
NYSE:BRC
NYSE:BRCCommercial Services

Did Brady’s New Portable i4311 Printer Redefine Field Labeling Enough to Shift BRC’s Narrative?

Heilind Electronics recently announced the availability of Brady Corporation’s i4311 Industrial Label Printer, the first portable model combining a swappable all-day battery, ergonomic carrying handle, and the ability to print labels up to 4.25 inches wide. This hybrid of benchtop performance and cordless mobility highlights Brady’s push to serve industrial users who need high-capability identification tools in the field as well as at the workstation. We’ll now examine how the i4311’s...
NasdaqGS:SVC
NasdaqGS:SVCHotel and Resort REITs

Will ESOP Share Offering and Reverse Split Reshape Service Properties Trust's (SVC) Capital Structure Narrative?

Service Properties Trust recently filed a US$7 million shelf registration to offer 800,000 common shares for an ESOP-related offering, following a one-for-five reverse stock split completed on July 7, 2026 and an unchanged quarterly cash distribution of US$0.05 per share. Together, these actions highlight how the REIT is adjusting its capital structure while using employee ownership and a maintained dividend to support stakeholder alignment. Now, we’ll consider how the new ESOP-related shelf...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

Extreme Networks (EXTR) Stock May Be 16% Undervalued Following Data Center Demand News

Extreme Networks stock has delivered a very strong 194.9% return over the past five years, and today the valuation picture shows a company that still screens as undervalued on both intrinsic value estimates and market multiples, but with only a mixed score when all checks are considered together. Over five years, Extreme Networks is up 194.9%, which puts recent pullbacks in a longer trend of substantial value creation for shareholders. Growing demand for data center networking equipment...
NYSE:WT
NYSE:WTCapital Markets

WisdomTree (WT) Looks Fully Valued As Space ETF Launch Draws Fresh Attention

WisdomTree (WT) is attracting fresh attention after launching the WisdomTree Space Economy Fund (WSPC) on Nasdaq, an actively managed ETF targeting companies tied to launch infrastructure, commercial space, defense applications, and emerging orbital technologies. See our latest analysis for WisdomTree. That launch lands at a time when WisdomTree’s momentum is already strong, with the share price at $20.16 and a 61.15% year to date share price return, alongside a very large 5 year total...
NYSE:EFX
NYSE:EFXProfessional Services

Equifax (EFX) Stock Could Be A Bargain On Cash Flow Yet Full On Earnings

Equifax stock has fallen 30.6% over the past year, yet the current valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while earnings-based multiples suggest the shares trade on the expensive side. Over the past 1 year, Equifax has declined 30.6%, which puts the recent share price under pressure even before considering what any valuation model implies. Planned expansion in Mexico through the agreed US$750m acquisition of...
NasdaqGS:VTRS
NasdaqGS:VTRSPharmaceuticals

Viatris (VTRS) Draws Fresh Attention Following Pain Management Partnership And Undervalued Narrative

Why Viatris Stock Is Back on Investors’ Radar Viatris (VTRS) is drawing attention after its role as a founding partner in the American Academy of Orthopaedic Surgeons’ new Pain Management Resource Center, a project focused on musculoskeletal pain care. This partnership arrives as Viatris trades at US$17.33, following a 3.8% move on July 16, 2026. This is prompting questions about how its healthcare collaborations and current valuation fit into a broader investment thesis. See our latest...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Synopsys (SNPS) Stock Could Trade Below Fair Value Despite Rich Earnings

Synopsys stock has pulled back over the past year, yet there is a clear split on value, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market multiples suggest the shares are on the expensive side. Over 5 years, Synopsys has delivered a gain of 48.1%, which puts the recent weakness into a longer track record of positive returns. The shift away from legacy manufacturing analytics toward AI driven chip design tools may support future cash flow,...
NYSE:ABBV
NYSE:ABBVBiotechs

AbbVie (ABBV) Boey Approval Puts Its Growth Story And Valuation Back In Focus

Why Boey’s European approval matters for AbbVie investors AbbVie (ABBV) is back in focus after Allergan Aesthetics secured European Commission approval for Boey, a rapid onset, short duration facial injectable that extends the company’s aesthetics reach across 30 European countries. This new product sits alongside growing interest in AbbVie’s neuroscience and immunology portfolios. It gives investors fresh information to consider when thinking about how different segments might support the...
NasdaqGS:HBT
NasdaqGS:HBTBanks

HBT Financial (HBT) Stock Looks Reasonable Rather Than Deeply Mispriced

After a 134.0% total return over the past 5 years, HBT Financial now trades at US$33.39. The central question is whether that performance is fully reflected in the price when set against its intrinsic value estimate and broader valuation checks. A 134.0% 5 year return indicates that long term shareholders in HBT Financial have already seen substantial value created, so any new position needs a clear view on remaining upside. The Excess Returns model suggests the intrinsic value sits...
NYSE:ARCO
NYSE:ARCOHospitality

How Investors Are Reacting To Arcos Dorados (ARCO) Redeeming Its 6.125% Sustainability-Linked Notes

Arcos Dorados Holdings Inc. has moved to redeem all of its outstanding 6.125% sustainability-linked senior notes due 2029, at 103.063% of principal plus accrued interest, with the redemption completed on July 16, 2026. This decision reshapes the company’s capital structure by retiring a relatively high-coupon instrument, potentially improving interest expense efficiency and highlighting management’s focus on balance sheet quality and financial flexibility. Next, we’ll examine how retiring...
NYSE:V
NYSE:VDiversified Financial

Visa Stock And 2 Fintech Picks For Rising Payment Fraud

Organized retail crime and rising tap to pay fraud are putting a fresh spotlight on the payment technology and fintech space, as retailers face security gaps, rising chargebacks, and the potential impact of new legislation like the Combating Organized Retail Crime Act. For investors, the question is which stocks could see stronger demand for their tools and services as the cost of fraud climbs toward an estimated $1b a year, and which might face higher risk. This article looks at 3 stocks...
NYSE:RNG
NYSE:RNGSoftware

RingCentral (RNG) Could Be 8% Undervalued After Mixed Earnings Signals

RingCentral (RNG) is back in focus after a mixed quarterly update, with revenue of $644.2 million meeting expectations while full-year EPS guidance topped forecasts, but billings and peer-relative performance fell short. See our latest analysis for RingCentral. RingCentral’s latest results landed after a strong run, with a 1-month share price return of 9.78% and year to date share price return of 51.40%. However, the stock is still working through mixed sentiment following the post earnings...
NasdaqGM:MAZE
NasdaqGM:MAZEPharmaceuticals

Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##

Maze Therapeutics stock has delivered a strong 59.2% return over the past year, yet its low value score and an overvalued read on market multiples suggest investors are paying up without a clear margin of safety. Over the last 12 months, Maze Therapeutics has returned 59.2%, which puts the spotlight on whether recent gains already reflect much of the good news investors expect. Future progress in turning its pipeline into consistent, scalable cash flows can support the current share price,...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Lumentum (LITE) Is Down 10.1% After AI Optics-Fueled Zacks Upgrade Has The Bull Case Changed?

Lumentum Holdings was recently upgraded by Zacks to a Rank #2 (Buy) after analysts raised earnings estimates amid rising demand for its optical components in AI-focused data centers, supported by fresh capital from an NVIDIA-led investment. This combination of stronger earnings expectations and AI data center exposure highlights how shifts in infrastructure spending can quickly reshape analyst views on Lumentum’s fundamentals. We’ll now examine how this Zacks upgrade, driven by higher...
NYSE:MOS
NYSE:MOSChemicals

Does Mosaic (MOS) Look Undervalued As Fertilizer Funding Meets Weaker Earnings And Tougher Markets?

Mosaic recently announced that it released its second quarter 2026 earnings on August 4 and held an investor call on August 5 to discuss results, against a backdrop of weaker earnings and ongoing operational challenges in key fertilizer markets. At the same time, analysts and investors are highlighting Mosaic’s apparent undervaluation and the US Department of Agriculture’s US$500 million fertilizer production funding as potentially supportive for the company’s long-term demand outlook...
NYSE:HEI
NYSE:HEIAerospace & Defense

HEICO (HEI) Stock Looks Fully Valued After A Strong Five Year Run

HEICO stock has returned 153.6% over the past five years, yet the current valuation checks paint a picture of shares trading at a premium, with both the intrinsic value estimate from a Discounted Cash Flow (DCF) approach and traditional multiples pointing to limited value on offer at today’s levels. Over five years, HEICO has delivered a 153.6% return, which puts extra focus on whether the current price leaves enough margin of safety for new capital. The recent $1.2b senior notes offering...
NYSE:OSK
NYSE:OSKMachinery

Oshkosh (OSK) Stock Looks Cheap On Cash Flow As Returns Stay Strong

Oshkosh stock has delivered a 67.8% return over the past three years, yet the latest intrinsic value work using a Discounted Cash Flow (DCF) approach still points to the shares trading at a discount of about 42.7% to that estimate, with the broader checks also leaning toward undervaluation. Over the past three years, Oshkosh has returned 67.8%. This puts recent gains into focus when weighing how much upside, if any, may be left in the current share price. Future valuation can be supported if...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) Names New COO As Production Ramp Narrative Puts Valuation In Focus

New COO Appointment Refocuses Attention On Enovix Operations Enovix (ENVX) has drawn fresh investor attention after appointing Dr. Michael Vyvoda as Chief Operating Officer, placing an operations veteran in charge of scaling its global lithium ion battery manufacturing footprint. See our latest analysis for Enovix. Enovix shares have been under pressure, with the latest close at $4.70 and the stock recording a 30 day share price return that is down 29.11%, while the 1 year total shareholder...
NasdaqGS:ALHC
NasdaqGS:ALHCHealthcare

Alignment Healthcare (ALHC) Faces Whistleblower Claims, Is The Stock Still Undervalued?

Whistleblower claims that Alignment Healthcare (ALHC) misclassified operating expenses as capital expenditures, allegedly inflating reported financial metrics, have prompted investigations by multiple law firms and put the stock and its accounting practices under closer scrutiny. See our latest analysis for Alignment Healthcare. Alignment Healthcare’s share price has come under pressure in the short term, with 1 day, 7 day and 90 day share price returns all declining. However, the 1 year...
NasdaqGS:VNOM
NasdaqGS:VNOMOil and Gas

3 Oil And Gas Stocks Retail Investors May Revisit After The Oil Price Spike

A sharp escalation in U.S. and Iran tensions, wider strikes across the region, and an 11% weekly jump in Brent and WTI futures have quickly reshaped the risk and return trade off around oil and gas. When the Strait of Hormuz and broader Middle East supply routes face higher disruption risk, some companies exposed to this news may see new opportunities while others confront added uncertainty and cost. This article walks through three stocks from the Energy Sector, Oil & Gas Producers screener...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

Legend Biotech (LEGN) Could Be 60% Undervalued Following CARVYKTI Sales Update

Legend Biotech (NasdaqGS:LEGN) is in focus after reporting that CARVYKTI® generated about US$657 million in net trade sales for the quarter ended June 30, 2026, based on figures provided by partner Janssen. See our latest analysis for Legend Biotech. Despite the CARVYKTI® sales update, Legend Biotech’s share price has been under pressure in the short term, with a 7 day share price return down 17.06% and a 30 day share price return down 31.97%, while the 1 year total shareholder return is down...